Renoprotective effects of telmisartan on renal injury in obese Zucker rats

Acta Diabetologica

Volumn 49, Issue 1 SUPPL., 2012, Pages

  Ohmura, T ^a   Tsunenari, I ^a   Seidler, R ^b   Chachin, M ^a   Hayashi, T ^a   Konomi, A ^a   Matsumaru, T ^a   Sumida, T ^a   Hayashi, N ^a   Horie, Y ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Diabetic nephropathy; Proteinuria; Renal fibrosis; Telmisartan; Type 2 diabetic mellitus

Indexed keywords

ENALAPRIL; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CHOLESTEROL; TRIACYLGLYCEROL;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; GLOMERULOSCLEROSIS; GLUCOSE TOLERANCE; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHEMISTRY; DRUG EFFECT; HUMAN; KIDNEY; METABOLISM; URINE; ZUCKER RAT;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; MALE; PROTEINURIA; RATS; RATS, ZUCKER; TRIGLYCERIDES; URINE;

EID: 84878895325     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-007-0016-5     Document Type: Article

References (41)

1. Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145-1151
2. Wolf G (1998) Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease. Nephrol Dial Transplant 13:1131-1142
3. Unger T, Cullman J, Gohlke P (1998) Clinical practice. Nephropathy in patients with type 2 diabetes. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 16:S3-S9
4. Timmermans PB, Duncia JV, Carini DJ, Chiu AT, Wong PC, Wexler RR, Smith RD (1995) Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens 9:S3-S18
5. Modlinger PS, Wilcox CS, Aslam S (2004) Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 24:354-365
6. Wolf G (2000) Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 15(Suppl 6):61-63
7. Chung O, Unger T (1998) Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol Dial Transplant 13:537-540
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 345:851-860
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfer S (2001) Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 345:861-869
10. Wienen W, Hauel N, Van Meel JC, Narr B, Ries U, Entzeroth M (1993) Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 110:245-252
11. Wienen W, Entzeroth M (1994) Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat. J Hypertens 12:119-128
12. Chachin M, Ohmura T, Hayashi N, Nishimura Y, Satoh H (2004) Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker. Folia Pharmacol Jpn 124:31-39
13. Barnett AH (2005) Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enaraprIL (DETAIL) study. Acta Diabetol 42:S42-S49
14. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S (2005) The telmisartan renoprotective study from incipient nephropathy to overt nephropathy-rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. J Int Med Res 33:677-686
15. Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, Lopez de Novales E (2005) Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 46:1074-1079
16. O'Donnell MP, Crary GS, Oda H, Kasiske BL, Powell JR, Keane WF (1997) Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int 52(Suppl 63):S218-S220
17. 1 receptors in an animal model of type 2 diabetes. Hypertens Res 25:271-278
18. Gonzalez-Albarran O, Gomez O, Ruiz E, Vieitez P, Garcia-Robles R (2003) Role of systolic blood pressure on the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). Am J Hypertens 16:979-985
19. 1 receptors increases survival of obese Zucker rats. Eur J Pharmacol 534:271-279
20. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T (2003) Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 26:413-9
21. Wienen W, Richard S, Champeroux P, Audeval-Gerard C (2001) Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin-Angiotensin- Aldosterone Syst 2:31-36
22. Zucker LM (1965) Hereditary obesity in the rat associated with hyperlipemia. Ann NY Acad Sci 131:447-458
23. Kasiske BL, O'Donnell MP, Keane WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19:I110-I115
24. Coimbra TM, Janssen U, Groene HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57:167-182
25. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E (1999) Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955
26. Yoshida M (1988) Exact probabilities associated with Tukey's and Dunnett's multiple comparisons procedures in imbalanced one-way ANOVA. J Japan Soc Comp Statist 1:111-122
27. Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y (2001) Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats). Jpn J Pharmacol 85:416-422
28. Kitamura H (2004) (Histopathology of diabetic nephropathy) Jin to Toseki (Kidney and Dialysis) 56:298-305
29. Li B, Yao J, Kawamura K, Oyanagi-Tanaka Y, Hoshiyama M, Morioka T, Gejyo F, Uchiyama M, Oite T (2004) Real-time observation of glomerular hemodynamic changes in diabetic rats: effects of insulin and ARB. Kidney Int 66:1939-1948
30. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T (2005) Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 16:3631-3641
31. Defferrari G, Ravera M, Defferrari L, Vettoretti S, Ratto E, Parodi D (2002) Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol 13:S224-S229
32. Long DA, Price KL, Herrera-Acosta J, Johnson RJ (2004) How does angiotensin II cause renal injury? Hypertension 43:722-723
33. Prieto-Carrasquero MC, Kobori H, Ozawa Y, Gutierrez A, Seth D, Navar LG (2004) AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Am J Physiol Renal Physiol 289:F632-F637
34. Pugsley MK (2005) The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 48:35-38
35. Fujihara CK, Velho M, Malheiros DM, Zats R (2005) An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67:1913-1924
36. Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y (2003) Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. J Nephrol 16:841-849
37. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 43:993-1002
38. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M (1998) Effect of troglitazone on microalbuminurea in patients with incipient diabetic nephropathy. Diabetes Care 21:2135-2139
39. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R (2000) Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49:1022-1032
40. Izzedine H, Launay-Vacher V, Buhaescu I, Heurtier A, Baumelou A, Deray G (2005) PPAR-gamma-agonists' renal effects. Minerva Urol Nephrol 57:247-260
41. Dominguez JH, Tang N, Xu W, Evan AP, Siakotos AN, Agarwal R, Walsh J, Deeg M, Pratt JH, March KL, Monnier VM, Weiss MF, Baynes JW, Peterson R (2000) Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 57:92-104